Evaluation of Desmoglein 1 and 3 Autoantibodies in Pemphigus Vulgaris: Correlation with Disease Severity

Overview

Journal J Clin Exp Dent

Specialty Dentistry

Date 2020 Jun 9

PMID 32509225

Citations 3

Authors

Zahra Delavarian

Pouran Layegh

Atessa Pakfetrat

Nazila Zarghi

Mahboubeh Khorashadizadeh

Ala Ghazi

Affiliations

Soon will be listed here.

Abstract

Background: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes caused by autoantibodies against desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3). Pemphigus vulgaris (PV) is the most common form of pemphigus. The aim of this study was to assess the correlation between the levels of anti-desmoglein 1 and 3 autoantibodies and the severity of PV disease.

Material And Methods: Nineteen newly diagnosed patients with pemphigus vulgaris were enrolled in this study. The titers of Dsg in subjects by using enzyme-linked immunosorbent assay (ELISA) were done at diagnosis time-point, 4th and 8th weeks after the initiation of treatment, and the correlation of antibodies with the oral and skin disease severity was evaluated.

Results: The severity of cutaneous lesions was significantly correlated with anti-Dsg1 titer in all visits and the severity of mucosal lesions was correlated with the titer of Dsg3 in the third visit (<0.001, 0.001, 0.016 and 0.015 value, respectively).

Conclusions: Anti-Dsg-1 autoantibodies titers seem to be more useful in showing the extent of the disease and activity in pemphigus with mucocutaneous lesions. Pemphigus vulgaris, Desmoglein (Dsg), Enzyme-linked immunosorbent assay (ELISA).

Citing Articles

IgG reactivity to different desmoglein-3 ectodomains in pemphigus vulgaris: novel panels for assessing disease severity.

Tavakolpour S, Noormohammadi Z, Daneshpazhooh M, Gholami A, Mahmoudi H Front Immunol. 2024; 15:1469937.

PMID: 39416775 PMC: 11479927. DOI: 10.3389/fimmu.2024.1469937.

Serological Biomarkers and Their Detection in Autoimmune Bullous Skin Diseases.

Heckler I, Hong M, Amart Sinha A, Venkataraman I Dermatol Pract Concept. 2022; 12(2):e2022116.

PMID: 35646449 PMC: 9116534. DOI: 10.5826/dpc.1202a116.

Pemphigus-The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic.

Marinovic B, Mise J, Lakos Jukic I, Bukvic Mokos Z Biomedicines. 2021; 9(11).

PMID: 34829784 PMC: 8615103. DOI: 10.3390/biomedicines9111555.

References

Bystryn J, Rudolph J . Pemphigus. Lancet. 2005; 366(9479):61-73. DOI: 10.1016/S0140-6736(05)66829-8. View

Schmidt E, Brocker E, Zillikens D . [Pemphigus. Loss of desmosomal cell-cell contact]. Hautarzt. 2000; 51(5):309-18. DOI: 10.1007/s001050051124. View

Van A, Nguyen T, Huu S, Thi L, Minh P, Huu N . Improving Treatment Outcome of Pemphigus Vulgaris on Vietnamese Patients by Using Desmoglein Elisa Test. Open Access Maced J Med Sci. 2019; 7(2):195-197. PMC: 6364727. DOI: 10.3889/oamjms.2019.003. View

Hallaji Z, Mortazavi H, Lajevardi V, Tamizifar B, Amirzargar A, Daneshpazhooh M . Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity. J Eur Acad Dermatol Venereol. 2009; 24(3):275-80. DOI: 10.1111/j.1468-3083.2009.03408.x. View

Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P . ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009; 145(5):529-35. DOI: 10.1001/archdermatol.2009.9. View

Lin N, Liu Q, Wang M, Wang Q, Zeng K . Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity. PeerJ. 2018; 6:e5388. PMC: 6078064. DOI: 10.7717/peerj.5388. View

De D, Khullar G, Handa S, Joshi N, Saikia B, Minz R . Correlation between salivary and serum anti-desmoglein 1 and 3 antibody titres using ELISA and between anti-desmoglein levels and disease severity in pemphigus vulgaris. Clin Exp Dermatol. 2017; 42(6):648-650. DOI: 10.1111/ced.13124. View

Michailidou E, Belazi M, Markopoulos A, Tsatsos M, Mourellou O, Antoniades D . Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007; 46(4):356-61. DOI: 10.1111/j.1365-4632.2006.03044.x. View

Belloni-Fortina A, Faggion D, Pigozzi B, Peserico A, Bordignon M, Baldo V . Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol. 2010; 2009:187864. PMC: 2798087. DOI: 10.1155/2009/187864. View

10.

Harman K, Seed P, Gratian M, Bhogal B, Challacombe S, Black M . The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001; 144(4):775-80. DOI: 10.1046/j.1365-2133.2001.04132.x. View

11.

Sitaru C, Zillikens D . Mechanisms of blister induction by autoantibodies. Exp Dermatol. 2005; 14(12):861-75. DOI: 10.1111/j.1600-0625.2005.00367.x. View

12.

Russo I, De Siena F, Saponeri A, Alaibac M . Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission. Medicine (Baltimore). 2017; 96(46):e8801. PMC: 5704887. DOI: 10.1097/MD.0000000000008801. View

13.

Harman K, Gratian M, Bhogal B, Challacombe S, Black M . A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000; 143(2):343-8. DOI: 10.1046/j.1365-2133.2000.03660.x. View

14.

Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A . Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol. 2007; 21(10):1319-24. DOI: 10.1111/j.1468-3083.2007.02254.x. View

15.

Murrell D, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz L . Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2018; 82(3):575-585.e1. PMC: 7313440. DOI: 10.1016/j.jaad.2018.02.021. View

16.

Sharma V, Prasad H, Khandpur S, Kumar A . Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris. Int J Dermatol. 2006; 45(5):518-22. DOI: 10.1111/j.1365-4632.2006.02593.x. View

17.

Scully C, Challacombe S . Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med. 2002; 13(5):397-408. DOI: 10.1177/154411130201300504. View

18.

Cholera M, Chainani-Wu N . Management of Pemphigus Vulgaris. Adv Ther. 2016; 33(6):910-58. PMC: 4920839. DOI: 10.1007/s12325-016-0343-4. View

19.

Silva D, Bernardes A . Pemphigus: cartography on the coordination of health policies. Cien Saude Colet. 2018; 23(8):2631-2640. DOI: 10.1590/1413-81232018238.14892016. View

20.

Ahmed A, Spigelman Z, Cavacini L, Posner M . Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006; 355(17):1772-9. DOI: 10.1056/NEJMoa062930. View